Although the feasibility of testing SGLT2 inhibitors like empagliflozin, or using oral KEs in BTHS appeared promising due to the reported actions of these agents on cardiac function in humans with heart failure, such an approach cannot be recommended based on our observations. Here, SLC5A2 is linked to heart failure.